Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | IL2 | P60568 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10835648 | 0.89 | KDM4E (0.50) | KDM4EIL2HTTATMALDH1A1 | |
| SCHEMBL7112634 | 0.89 | KDM4E (0.53) | KDM4EIL2HTTATMALDH1A1 | |
| SCHEMBL18380643 | 0.87 | KDM4E (0.61) | KDM4EHTTATMALDH1A1LMNA | |
| SCHEMBL29616919 | 0.87 | KDM4E (0.61) | KDM4EHTTATMALDH1A1LMNA | |
| SCHEMBL11491135 | 0.86 | KDM4E (0.47) | KDM4EIL2HTTATMALDH1A1 | |
| SCHEMBL8486524 | 0.86 | KDM4E (0.46) | KDM4EIL2HTTATMALDH1A1 | |
| SCHEMBL7934334 | 0.84 | KDM4E (0.45) | KDM4EIL2HTTATMALDH1A1 | |
| SCHEMBL7004170 | 0.84 | KDM4E (0.45) | KDM4EIL2HTTATMALDH1A1 | |
| SCHEMBL11485826 | 0.84 | KDM4E (0.45) | KDM4EIL2HTTATMALDH1A1 | |
| SCHEMBL3942245 | 0.83 | KDM4E (0.53) | KDM4EIL2HTTATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563586-B2 | 1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation | ELDRUG S.A. (GR) | 2013-10-22 | — | — | US | disclosed |
| US-8563586-B2 | 1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation | ELDRUG S.A. (GR) | 2013-10-22 | — | — | US | disclosed |
| US-20100166837-A1 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | ELDRUG S.A. (GR) | 2010-07-01 | — | — | US | disclosed |
| US-20100166837-A1 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | ELDRUG S.A. (GR) | 2010-07-01 | — | — | US | disclosed |
| WO-2008142576-A2 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | ELDRUG S.A. (GR) | 2008-11-27 | — | — | WO | disclosed |
| EP-1169289-B1 | METHOD FOR PRODUCING DERIVATIVES OF BIPHENYL-2-CARBOXYLIC ACID | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-10-29 | — | — | EP | disclosed |
| WO-2003066626-A1 | DEUTERATED BIPHENYL-SUBSTITUTED BENZIMIDAZOLES AND MEDICAMENT CONTAINING SAID COMPOUNDS FOR THE TREATMENT OF HYPERTONIA | TURICUM DRUG DEVELOPMENT AG (CH) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003066565-A1 | DEUTERATED BIPHENYL DERIVATIVES | TURICUM DRUG DEVELOPMENT AG (CH) | 2003-08-14 | — | — | WO | disclosed |
| US-6369271-B1 | SAPONIFICATION WITH HYDROCHLORIC ACID, HEATING WITH PRESSURIZATION | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-04-09 | — | — | US | disclosed |
| EP-1169289-A1 | METHOD FOR PRODUCING DERIVATIVES OF BIPHENYL-2-CARBOXYLIC ACID | Boehringer Ingelheim Pharma KG (DE) | 2002-01-09 | — | — | EP | disclosed |
| US-5288895-A | Reacting a benzonitrile halide with methylphenylmagnisium halide in the presence of manganous salt, hydrolyzing the forming complexes | ELF SANOFI (FR) | 1994-02-22 | — | — | US | disclosed |
| US-5155118-A | Administering angiotensin inhibitor | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| US-5153197-A | Treatment of hypertension with angiotensin II blocking imidazoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-5138069-A | Treating hypertension and congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| US-5128355-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0470795-A1 | Process for the manufacture of nitriles | ZENECA LIMITED (GB) | 1992-02-12 | — | — | EP | disclosed |
| EP-0470794-A1 | Process for the preparation of nitriles | ZENECA LIMITED (GB) | 1992-02-12 | — | — | EP | disclosed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | disclosed |
| EP-0253310-A2 | Angiotensin II receptor blocking imidazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166837-A1 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | AGTR1, AGTR2, AGT | KDM4E 1972/4885IL2 2749/4885HTT 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.